A drug delivery device includes a drug-eluting element defined by a plurality of outer surfaces including a delivery surface and one or more other non-delivery surfaces. The delivery surface is positioned against tissue of an eye and shaped to define an area of targeted tissue to receive a drug. The drug-eluting element holds the drug when the delivery surface is not positioned against the tissue. Responsive to the delivery surface being positioned against the tissue, the drug-eluting element releases the drug to the area of targeted tissue through the delivery surface. The drug delivery device includes one or more barrier structures disposed along the one or more non-delivery surfaces of the drug-eluting element. The one or more barrier structures substantially inhibit release of the drug from the drug-eluting element through the one or more non-delivery surfaces.

Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.

Methods and kits for treating or preventing an eye condition or for cleaning an eye area tissue are provided. A method of the invention includes administering an isoprenoidal essential oil to eye area tissue, chafing eye area tissue with an abrasive, and removing the abrasive. A kit according to the invention includes an isoprenoidal essential oil, an abrasive for chafing eye area tissue, and in instruction for use for treating an eye condition or cleansing an eye area tissue. The invention also includes a composition of matter comprising an isoprenoidal essential oil and a plurality of abrasive particles in ophthamologically acceptable base.

Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

A plug member integrally includes a base portion (35a) attached to a plug holder (31) to be mounted on a mouth portion of a container, a plug (34) engaged with an engagement portion (31c) provided in an outlet passage of the plug holder (31), and a resilient connection portion (35b) resiliently connecting the plug (34) to the base portion (35a). Before the first use, the outlet passage is closed with the plug member. In the first use, the container is squeezed to increase the internal pressure of the container. Thus, the plug (34) is disengaged from the engagement portion (31c) by the internal pressure. The outlet passage is thereafter constantly kept open.

A dry eye treatment device and method including a pliable thermal pack engageable upon a first side of a vibration ring is provided. The vibration ring has a second side adapted for positioning on the face of a user to communicate vibration to the eyelids of a user from the vibration ring, and heat or cold from a bulging portion of the thermal pack communicating through a pair of openings in the vibration ring. A cover forming a cavity on the face of the user to house the vibration ring and the thermal pack may also be employed.

Systems and methods are provided for generating and applying artificial tear film layers to a cornea surface. An example method includes forming an artificial tear film that is optically transparent, ultra-thin, and smoothly conforming to cornea surface. The artificial tear film includes a lipid layer that prevents evaporation of moisture from the cornea (e.g., from the underlying aqueous layer of the artificial tear film, and/or from the natural tear film on the cornea, etc.). A dispenser, such as an atomizer/nebulizer/micronizer, can be used to generate and applying the artificial tear film layers, especially the lipid layer, with reduced dispensing volume and average droplet size, etc., such that the deposit thickness of the artificial tear film layers remains thin and better spreads and conforms to the surface of the cornea, as compared to the results of conventional eye droppers dispensing conventional artificial tears.

A locking mechanism for an aerosol dispenser is presented having a first body structure, a second body structure rotatably attached to the first body structure, a spindle rotatably attached to the second body structure, the spindle having an actuator rotationally cooperating with the first body structure such that rotation of the first body structure relative to the second body structure causes rotation of the actuator and of the spindle, a movable element arranged around the spindle, the spindle being rotatable relative to the movable element, wherein rotation of the spindle causes movement of the movable element along the spindle from an initial position to a final position, and a locking element, wherein in the final position the movable element applies a radial force onto the locking element causing the locking element to bend in the radial direction thereby preventing rotation between the first body structure and the second body structure.

According to one aspect of the disclosure, an apparatus for manipulating a sclera to facilitate delivery of a medicament to a suprachoroidal space of an eye may include a needle with a sharp distalmost tip, a needle hub connected to a proximal end of the needle, a housing surrounding the needle hub and extending from a proximal end of the needle hub, and an adaptor surrounding a portion of the needle.